Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology (ASH) Annual Meeting

7/9 (77.8%) evaluable subjects exhibited clinical benefit, including three complete responses and two partial responses Reproducible survivin-specific T cell responses

Read more

Greenwich Biosciences, a GW Pharmaceuticals Company, Presents New Data for EPIDIOLEX® (cannabidiol) in Patients with Tuberous Sclerosis Complex (TSC) at the American Epilepsy Society Annual Meeting

CARLSBAD, Calif., Dec. 07, 2019 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development,

Read more

BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death

Read more

Diyotta and CTI Partners Announce Strategic Partnership to Deliver Data Warehousing and Analytics Solutions For Healthcare in Record Time

CHARLOTTE, N.C., Nov. 2, 2019 /PRNewswire-PRWeb/ — Diyotta, Inc., an enterprise-class, data integration platform for modern data environments, today announced a

Read more

Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted Therapy

BARCELONA, Spain, Sept. 28, 2019 (GLOBE NEWSWIRE) — Guardant Health and the National Cancer Center Hospital East will present data

Read more
Show Buttons
Hide Buttons